On the other hand, only topically applied inhibitor reduced serum levels of IgE and upregulated the expression of FLG. Mentioned-above discrepancies, despite similar clinical effectiveness, resulted from the route of administration of the Hsp90 inhibitor to mice with AD. Here, HSP90AA1 is linked to Alzheimer disease.